Caitlin Raymond: Practicing at the Edge of ABO – Navigating Rare A Subgroups
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at the University of Wisconsin-Madison, shared on LinkedIn:
”I just published a new post on Blood, Bytes, and Beyond: “Practicing at the Edge of ABO: Navigating Rare A Subgroups.”
In transfusion medicine, we talk a lot about “weak A” phenotypes — but biologically and clinically, they’re not all the same.
A3, Aw, and Ael arise through different mechanisms, carry different degrees of antigen expression, and sit in very different evidence spaces when it comes to transfusion risk.
This piece grew out of a real on-service case, where the literature didn’t quite tell us what to do, and judgment mattered as much as data.
It’s a reflection on how we make conservative decisions when incidence data are sparse, case reports loom large, and the downside of being wrong is asymmetric.
If you work in transfusion medicine, blood banking, or laboratory medicine more broadly — or if you’re interested in how clinicians navigate uncertainty at the bedside — I’d love for you to read it.”
Read the full post here.
Stay updated with Hemostasis Today.
-
Jan 18, 2026, 10:11Adrien Bouglé on Comparison Between Regional Citrate Anticoagulation and Systemic Heparin
-
Jan 18, 2026, 09:48Ed Beveridge Shares A New Guide on VTE Prophylaxis in Psychiatric Illness
-
Jan 18, 2026, 08:11Ardis Callie on Standardisation and Documentation of VTE Risk Assessments
-
Jan 18, 2026, 06:07Alan Nurden Shares A Study on Unusual Form of Glanzmann Thrombasthenia
-
Jan 18, 2026, 05:51Shiny K Kajal on Transfusion Medicine: From Trial and Error to Life-Saving Science
-
Jan 18, 2026, 05:40Abdul Mannan: Why Your Patient on Metformin is Losing B12
-
Jan 17, 2026, 22:13Neil Blumberg on Massive Transfusion in Trauma and Hemorrhagic Emergencies
-
Jan 17, 2026, 14:30Jecko Thachil Shares a Perspective on von Willebrand Disease
-
Jan 17, 2026, 14:16Fadi Alshrouf Explains Red Blood Cell Exchange